Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2025-12-25 @ 10:39 PM
Study NCT ID:
NCT07166367
Status:
TERMINATED
Last Update Posted:
2025-09-10
First Post:
2025-09-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
Sponsor:
National Cancer Centre, Singapore
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-11
Start Date Type:
ACTUAL
Primary Completion Date:
2020-01-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-01-14
Completion Date Type:
ACTUAL
First Submit Date:
2025-09-03
First Submit QC Date:
None
Study First Post Date:
2025-09-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-03
Last Update Post Date:
2025-09-10
Last Update Post Date Type:
ESTIMATED